A Randomized, Double-Blind Placebo Controlled, Parallel Groups Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by MRI
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2016
At a glance
- Drugs MK 0812 (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 29 Jul 2016 Status changed from completed to discontinued.
- 14 May 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
- 18 Dec 2005 New trial record.